86d82b6b3b593f3a…

{
  "id": "NCT00001662",
  "type": "Study",
  "data": {
    "briefSummary": "Glutamate is an amino acid released by brain cells that acts to excite other cells. Glutamate attaches to special sites on cells called AMPA (alpha-amino-2,3-dihydro-5 methyl 3-oxo-4-isoxazolepropanoic acid) receptors. The brain cells responsible for releasing glutamate are damaged in Alzheimer's disease and other conditions affecting thinking and reasoning.\n\nResearchers would like to see if giving patients a drug that attaches to AMPA receptors improves the symptoms of Alzheimer's disease.\n\nCX516 (Ampalex) is a test drug that affects the AMPA receptors. This study will investigate the effectiveness and safety of CX516 on patients with Alzheimer's disease.\n\nPatients will be given capsules of CX516 or placebo (sugar pill that neither harms nor helps) for up to 16 weeks in different amounts. The effectiveness of the drug will be measured by neurological tests. Safety will be monitored by frequent check-ups and lab examinations.",
    "completionDate": "2005-11",
    "conditions": [
      "Alzheimer's Disease",
      "Dementia"
    ],
    "enrollmentCount": 40,
    "enrollmentType": null,
    "nctId": "NCT00001662",
    "phase": "PHASE2",
    "sponsorId": "national-institute-of-neurological-disorders-and-stroke-ninds",
    "startDate": "1996-12",
    "status": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "title": "Tolerability and Primary Efficacy of CX516 in Alzheimer's Disease",
    "url": "https://clinicaltrials.gov/study/NCT00001662"
  }
}